-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Victory Capital Management Inc. Invests $279,000 in Bioventus Inc. (NYSE:BVS)
Victory Capital Management Inc. Invests $279,000 in Bioventus Inc. (NYSE:BVS)
Victory Capital Management Inc. purchased a new stake in Bioventus Inc. (NYSE:BVS – Get Rating) during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 23,208 shares of the company's stock, valued at approximately $279,000.
A number of other hedge funds have also bought and sold shares of BVS. Nuance Investments LLC grew its position in shares of Bioventus by 10.7% during the 4th quarter. Nuance Investments LLC now owns 1,275,040 shares of the company's stock worth $18,475,000 after purchasing an additional 123,283 shares in the last quarter. Tamarack Advisers LP raised its holdings in Bioventus by 82.3% in the 4th quarter. Tamarack Advisers LP now owns 875,000 shares of the company's stock valued at $12,679,000 after acquiring an additional 395,000 shares in the last quarter. Rice Hall James & Associates LLC lifted its position in shares of Bioventus by 44.6% during the 4th quarter. Rice Hall James & Associates LLC now owns 536,098 shares of the company's stock valued at $7,768,000 after acquiring an additional 165,269 shares during the period. Soleus Capital Management L.P. lifted its position in shares of Bioventus by 352.8% during the 4th quarter. Soleus Capital Management L.P. now owns 428,397 shares of the company's stock valued at $6,207,000 after acquiring an additional 333,795 shares during the period. Finally, Northern Trust Corp grew its holdings in shares of Bioventus by 89.0% during the 4th quarter. Northern Trust Corp now owns 258,899 shares of the company's stock worth $3,752,000 after purchasing an additional 121,887 shares in the last quarter. 86.85% of the stock is owned by institutional investors.
Get Bioventus alerts:Analyst Ratings Changes
Separately, Morgan Stanley boosted their price target on Bioventus from $11.00 to $12.00 and gave the company an "overweight" rating in a research note on Friday, August 12th.
Bioventus Stock Down 2.8 %
Shares of BVS opened at $8.23 on Monday. The firm has a 50 day simple moving average of $8.15 and a two-hundred day simple moving average of $10.50. The company has a market cap of $634.92 million, a P/E ratio of -24.21 and a beta of 2.07. Bioventus Inc. has a one year low of $6.30 and a one year high of $17.53. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.39 and a quick ratio of 1.05.Bioventus (NYSE:BVS – Get Rating) last posted its quarterly earnings results on Thursday, August 11th. The company reported $0.10 EPS for the quarter, missing analysts' consensus estimates of $0.14 by ($0.04). The business had revenue of $140.33 million for the quarter, compared to analyst estimates of $140.01 million. Bioventus had a positive return on equity of 10.35% and a negative net margin of 4.26%. During the same period last year, the firm posted $0.16 EPS. Research analysts forecast that Bioventus Inc. will post 0.54 EPS for the current fiscal year.
About Bioventus
(Get Rating)
Bioventus Inc a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products.
Read More
- Get a free copy of the StockNews.com research report on Bioventus (BVS)
- 2 EV Suppliers Powering To Gains After Raising Views
- Applied Materials Results Show A Slowing Semiconductor Market
- MarketBeat: Week in Review 8/15 – 8/19
- Near-Term Headwinds Present An Opportunity In Ross Stores
- Apple's Stock Could Be On The Verge Of Another 30% Rally
Want to see what other hedge funds are holding BVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bioventus Inc. (NYSE:BVS – Get Rating).
Receive News & Ratings for Bioventus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventus and related companies with MarketBeat.com's FREE daily email newsletter.
Victory Capital Management Inc. purchased a new stake in Bioventus Inc. (NYSE:BVS – Get Rating) during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 23,208 shares of the company's stock, valued at approximately $279,000.
根据最近提交给证券交易委员会的13F文件,胜利资本管理公司在第一季度购买了Bioventus Inc.(纽约证券交易所代码:BVS-GET Rating)的新股份。该机构投资者购买了23,208股该公司股票,价值约279,000美元。
A number of other hedge funds have also bought and sold shares of BVS. Nuance Investments LLC grew its position in shares of Bioventus by 10.7% during the 4th quarter. Nuance Investments LLC now owns 1,275,040 shares of the company's stock worth $18,475,000 after purchasing an additional 123,283 shares in the last quarter. Tamarack Advisers LP raised its holdings in Bioventus by 82.3% in the 4th quarter. Tamarack Advisers LP now owns 875,000 shares of the company's stock valued at $12,679,000 after acquiring an additional 395,000 shares in the last quarter. Rice Hall James & Associates LLC lifted its position in shares of Bioventus by 44.6% during the 4th quarter. Rice Hall James & Associates LLC now owns 536,098 shares of the company's stock valued at $7,768,000 after acquiring an additional 165,269 shares during the period. Soleus Capital Management L.P. lifted its position in shares of Bioventus by 352.8% during the 4th quarter. Soleus Capital Management L.P. now owns 428,397 shares of the company's stock valued at $6,207,000 after acquiring an additional 333,795 shares during the period. Finally, Northern Trust Corp grew its holdings in shares of Bioventus by 89.0% during the 4th quarter. Northern Trust Corp now owns 258,899 shares of the company's stock worth $3,752,000 after purchasing an additional 121,887 shares in the last quarter. 86.85% of the stock is owned by institutional investors.
其他一些对冲基金也买卖了BVS的股票。Nuance Investments LLC在第四季度将其在Bioventus股票的头寸增加了10.7%。Nuance Investments LLC在上个季度额外购买了123,283股后,现在拥有1,275,040股该公司股票,价值18,475,000美元。Tamarack Advisers LP在第四季度将其在Bioventus的持股增加了82.3%。Tamarack Advisers LP在上个季度增持了395,000股后,现在拥有875,000股该公司股票,价值12,679,000美元。莱斯·霍尔·詹姆斯联合有限责任公司第四季度将其在Bioventus股票中的头寸提高了44.6%。莱斯·霍尔·詹姆斯和合伙人有限责任公司目前拥有536,098股该公司的股票,价值7,768,000美元,在此期间又购买了165,269股。Soleus Capital Management L.P.在第四季度将其在Bioventus股票的头寸提高了352.8%。Soleus Capital Management L.P.在此期间增持了333,795股,现在拥有428,397股该公司股票,价值6,207,000美元。最后,北方信托公司在第四季度增持了89.0%的Bioventus股票。Northern Trust Corp目前持有258,899股该公司股票,价值3,752,000美元,此前该公司在上个季度又购买了121,887股。86.85%的股份由机构投资者持有。
Analyst Ratings Changes
分析师评级发生变化
Separately, Morgan Stanley boosted their price target on Bioventus from $11.00 to $12.00 and gave the company an "overweight" rating in a research note on Friday, August 12th.
另外,摩根士丹利在8月12日(星期五)的一份研究报告中将Bioventus的目标价从11.00美元上调至12.00美元,并给予该公司“增持”评级。
Bioventus Stock Down 2.8 %
Bioventus股价下跌2.8%
Bioventus (NYSE:BVS – Get Rating) last posted its quarterly earnings results on Thursday, August 11th. The company reported $0.10 EPS for the quarter, missing analysts' consensus estimates of $0.14 by ($0.04). The business had revenue of $140.33 million for the quarter, compared to analyst estimates of $140.01 million. Bioventus had a positive return on equity of 10.35% and a negative net margin of 4.26%. During the same period last year, the firm posted $0.16 EPS. Research analysts forecast that Bioventus Inc. will post 0.54 EPS for the current fiscal year.
Bioventus(纽约证券交易所代码:BVS-GET Rating)最近一次公布季度收益是在8月11日星期四。该公司公布本季度每股收益为0.10美元,低于分析师普遍预期的0.14美元(0.04美元)。该业务本季度营收为1.4033亿美元,而分析师预期为1.401亿美元。Bioventus的股本回报率为正10.35%,净利润率为负4.26%。去年同期,该公司公布的每股收益为0.16美元。研究分析师预测,Bioventus Inc.本财年每股收益将为0.54美元。
About Bioventus
关于Bioventus
(Get Rating)
(获取评级)
Bioventus Inc a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products.
Bioventus公司是一家医疗设备公司,专注于开发临床治疗方法并将其商业化,这些治疗方法在美国和国际上参与并增强了人体的自然愈合过程。该公司的产品组合包括疼痛治疗,其中包括非手术关节疼痛注射疗法,以及周围神经刺激产品。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on Bioventus (BVS)
- 2 EV Suppliers Powering To Gains After Raising Views
- Applied Materials Results Show A Slowing Semiconductor Market
- MarketBeat: Week in Review 8/15 – 8/19
- Near-Term Headwinds Present An Opportunity In Ross Stores
- Apple's Stock Could Be On The Verge Of Another 30% Rally
- 免费获取StockNews.com关于Bioventus(BVS)的研究报告
- 2家电动汽车供应商在提出意见后上涨
- 应用材料公司业绩显示半导体市场放缓
- MarketBeat:回顾中的一周8/15-8/19
- 近期逆风为Ross Stores带来机遇
- 苹果股价可能再次上涨30%
Want to see what other hedge funds are holding BVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bioventus Inc. (NYSE:BVS – Get Rating).
想看看其他对冲基金持有BVS吗?访问HoldingsChannel.com获取Bioventus Inc.(纽约证券交易所代码:BVS-GET Rating)的最新13F文件和内幕交易。
Receive News & Ratings for Bioventus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventus and related companies with MarketBeat.com's FREE daily email newsletter.
收到《Bioventus Daily》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Bioventus和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧